Elexacaftor and tezacaftor work to improve cellular processing and trafficking, allowing for more CFTR proteins to come to the cell surface ...

TRIKAFTA adds elexacaftor to tezacaftor and ivacaftor to target CFTR protein defects caused by the F508del mutation or another mutation responsive to TRIKAFTA.

3 июл. 2021 г. · Trikafta is the combination of two correctors (TEZ and ELX) and a potentiator (IVA). IVA directly targets mutant CFTR channel-forming protein.

Elexacaftor/tezacaftor/ivacaftor is composed of a combination of ivacaftor, a chloride channel opener, and elexacaftor and tezacaftor, CFTR modulators.

20 мая 2019 г. · Elexacaftor is a CFTR corrector that modulates CFTR proteins to facilitate trafficking to the cell surface for incorporation into the cell membrane.

Mechanism of Action. Ivacaftor functions as a potentiator of the CFTR protein for common gating mutations, allowing for an increase in chloride ion flow.

The CFTR modulator Trikafta (elexacaftor/tezacaftor/ivacaftor) combines the correctors elexacaftor and tezacaftor, which help to fix flaws in the CFTR protein ...

11 мар. 2020 г. · This drug's mechanism of action means it treats the underlying genetic cause of the disease in 90% of the CF population.

This protein acts as a channel and allows for the passage of chloride and sodium.